StimCardio Medical, Inc. — SEC Form D Filing

StimCardio Medical, Inc. filed an SEC Form D on July 29, 2026, reporting $24.95M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
July 29, 2026
Amount reported
$24.95M
Round stage
Seed
Industry
Medical Devices
Website
https://www.stimcardio.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Atrial fibrillation (AF) affects over 52.5 million people worldwide, carrying a significantly increased risk of ischemic stroke and high recurrence rates. Current management of this cardiac rhythm disorder leads to substantial healthcare costs and frequent hospitalizations.

Solution

StimCardio Medical is developing a non-invasive, wearable neuromodulation platform called Rhyvive™ that integrates continuous physiological sensing with personalized therapy. This system is designed to monitor patients, analyze cardiac and autonomic signals, and deliver personalized peripheral neuromodulation to reduce atrial fibrillation burden by restoring autonomic balance.

Why now

Growing prevalence of atrial fibrillation, advancements in wearable technology for physiological monitoring, and increasing interest in non-pharmacological, personalized treatment options for chronic conditions.

Verdict

This cleared because it presented a novel, non-invasive approach to a prevalent chronic condition with clear unmet needs, not because it demonstrated immediate market access or a scalable sales channel. Investors implicitly bet on the clinical efficacy of neuromodulation for AFib and the potential for a new standard of care in chronic disease management that avoids invasive procedures or pharmaceutical side effects. The upside was capped by regulatory hurdles and the inherent challenges of patient and physician adoption for a new therapeutic modality.

Source: SEC EDGAR Form D filing